These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

487 related items for PubMed ID: 17461994

  • 1. Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation.
    Busca A, de Fabritiis P, Ghisetti V, Allice T, Mirabile M, Gentile G, Locatelli F, Falda M.
    Transpl Infect Dis; 2007 Jun; 9(2):102-7. PubMed ID: 17461994
    [Abstract] [Full Text] [Related]

  • 2. Valganciclovir as pre-emptive therapy for cytomegalovirus infection in allogeneic haematopoietic stem cell transplant recipients.
    Ruiz-Camps I, Len O, de la Cámara R, Gurguí M, Martino R, Jarque I, Barrenetxea C, Díaz de Heredia C, Batlle M, Rovira M, de la Torre J, Torres A, Aguilar M, Espigado I, Martín-Dávila P, Bou G, Borrell N, Aguado JM, Pahissa A, Spanish Network for Research on Infection in Transplantation (RESITRA/REIPI). Spain.
    Antivir Ther; 2011 Jun; 16(7):951-7. PubMed ID: 22024510
    [Abstract] [Full Text] [Related]

  • 3. Low-dose valgancyclovir as cytomegalovirus reactivation prophylaxis in allogeneic haematopoietic stem cell transplantation.
    Serio B, Rosamilio R, Giudice V, Pepe S, Zeppa P, Esposiito S, Pezzullo L, Rocco M, Montuori N, Selleri C.
    Infez Med; 2012 Jun; 20 Suppl 2():26-34. PubMed ID: 23042003
    [Abstract] [Full Text] [Related]

  • 4. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
    Witzke O, Hauser IA, Bartels M, Wolf G, Wolters H, Nitschke M, VIPP Study Group.
    Transplantation; 2012 Jan 15; 93(1):61-8. PubMed ID: 22094954
    [Abstract] [Full Text] [Related]

  • 5. Valganciclovir for pre-emptive therapy of cytomegalovirus viraemia after hematopoietic stem cell transplantation: a prospective multi-center trial.
    Liu KY, Wang Y, Han MZ, Huang H, Chen H, Liu QF, Wang JM, Liu T, Song YP, Ma J, Wu DP, Zou P, Huang XJ.
    Chin Med J (Engl); 2010 Aug 15; 123(16):2199-205. PubMed ID: 20819665
    [Abstract] [Full Text] [Related]

  • 6. Initial low-dose valganciclovir as a preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients.
    Takenaka K, Nagafuji K, Takase K, Kamimura T, Mori Y, Ito Y, Nishi Y, Henzan H, Kato K, Harada N, Eto T, Miyamoto T, Teshima T, Akashi K.
    Int J Hematol; 2012 Jul 15; 96(1):94-100. PubMed ID: 22547196
    [Abstract] [Full Text] [Related]

  • 7. Occurrence of adverse events caused by valganciclovir as pre-emptive therapy for cytomegalovirus infection after allogeneic stem cell transplantation is reduced by low-dose administration.
    Takahata M, Hashino S, Nishio M, Sugita J, Shigematsu A, Onozawa M, Fujimoto K, Endo T, Kondo T, Tanaka J, Imamura M, Teshima T.
    Transpl Infect Dis; 2015 Dec 15; 17(6):810-5. PubMed ID: 26354293
    [Abstract] [Full Text] [Related]

  • 8. Successful preemptive cidofovir treatment for CMV antigenemia after dose-reduced conditioning and allogeneic blood stem cell transplantation.
    Platzbecker U, Bandt D, Thiede C, Helwig A, Freiberg-Richter J, Schuler U, Plettig R, Geissler G, Rethwilm A, Ehninger G, Bornhäuser M.
    Transplantation; 2001 Apr 15; 71(7):880-5. PubMed ID: 11349720
    [Abstract] [Full Text] [Related]

  • 9. Use of the cytomegalovirus pp65 antigenemia assay for preemptive therapy in allogeneic hematopoietic stem cell transplantation: a real-world review.
    Tan BH, Chlebicka NL, Low JG, Chong TY, Chan KP, Goh YT.
    Transpl Infect Dis; 2008 Oct 15; 10(5):325-32. PubMed ID: 18627578
    [Abstract] [Full Text] [Related]

  • 10. Qualitative plasma PCR assay (AMPLICOR CMV test) versus pp65 antigenemia assay for monitoring cytomegalovirus viremia and guiding preemptive ganciclovir therapy in allogeneic stem cell transplantation.
    Solano C, Muñoz I, Gutiérrez A, Farga A, Prósper F, García-Conde J, Navarro D, Gimeno C.
    J Clin Microbiol; 2001 Nov 15; 39(11):3938-41. PubMed ID: 11682510
    [Abstract] [Full Text] [Related]

  • 11. Oral Valganciclovir as a Preemptive Treatment for Cytomegalovirus (CMV) Infection in CMV-Seropositive Liver Transplant Recipients.
    Kim JM, Kwon CH, Joh JW, Ha YE, Sinn DH, Choi GS, Peck KR, Lee SK.
    PLoS One; 2015 Nov 15; 10(5):e0123554. PubMed ID: 25942443
    [Abstract] [Full Text] [Related]

  • 12. High efficacy and low toxicity of short-course oral valganciclovir as pre-emptive therapy for hematopoietic stem cell transplant cytomegalovirus infection.
    Saleh AJ, Al Mohareb F, Al Rabiah F, Chaudhri N, Al Sharif F, Al Zahrani H, Mohamed SY, Patel M, Rasheed W, Nurgat Z, Bakr M, Ahmed S, Zaidi S, Nasser A, Ibrahim K, Al Abdely H, Aljurf M.
    Hematol Oncol Stem Cell Ther; 2010 Nov 15; 3(3):116-20. PubMed ID: 20890068
    [Abstract] [Full Text] [Related]

  • 13. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
    George B, Pati N, Gilroy N, Ratnamohan M, Huang G, Kerridge I, Hertzberg M, Gottlieb D, Bradstock K.
    Transpl Infect Dis; 2010 Aug 01; 12(4):322-9. PubMed ID: 20487414
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of preemptive anti-CMV therapy with valganciclovir after kidney transplantation.
    Lopau K, Greser A, Wanner C.
    Clin Transplant; 2007 Aug 01; 21(1):80-5. PubMed ID: 17302595
    [Abstract] [Full Text] [Related]

  • 15. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation.
    Reusser P, Einsele H, Lee J, Volin L, Rovira M, Engelhard D, Finke J, Cordonnier C, Link H, Ljungman P, Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
    Blood; 2002 Feb 15; 99(4):1159-64. PubMed ID: 11830461
    [Abstract] [Full Text] [Related]

  • 16. Forscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): a randomised study.
    Moretti S, Zikos P, Van Lint MT, Tedone E, Occhini D, Gualandi F, Lamparelli T, Mordini N, Berisso G, Bregante S, Bruno B, Bacigalupo A.
    Bone Marrow Transplant; 1998 Jul 15; 22(2):175-80. PubMed ID: 9707026
    [Abstract] [Full Text] [Related]

  • 17. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K, Nishida T, Asano-Mori Y, Oshima K, Ohashi K, Mori T, Kanamori H, Miyamura K, Kato C, Kobayashi N, Uchida N, Nakamae H, Ichinohe T, Morishima Y, Suzuki R, Yamaguchi T, Fukuda T.
    Biol Blood Marrow Transplant; 2015 Nov 15; 21(11):2008-16. PubMed ID: 26211985
    [Abstract] [Full Text] [Related]

  • 18. Oral valganciclovir versus intravenous ganciclovir as preemptive treatment for cytomegalovirus infection after living donor liver transplantation: a randomized trial.
    Togashi J, Sugawara Y, Hashimoto M, Tamura S, Kaneko J, Aoki T, Hasegawa K, Kokudo N.
    Biosci Trends; 2011 Nov 15; 5(5):217-22. PubMed ID: 22101378
    [Abstract] [Full Text] [Related]

  • 19. Half-dose ganciclovir preemptive treatment of cytomegalovirus infection after pediatric allogeneic hematopoietic stem cell transplantation.
    Ju HY, Kang HJ, Hong CR, Lee JW, Kim H, Park KD, Shin HY, Park JD, Choi EH, Lee HJ, Ahn HS.
    Transpl Infect Dis; 2016 Jun 15; 18(3):396-404. PubMed ID: 27041364
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of low-dose ganciclovir preemptive therapy in allogeneic haematopoietic stem cell transplant recipients compared with conventional-dose ganciclovir: a prospective observational study.
    Park SY, Lee SO, Choi SH, Kim YS, Woo JH, Baek S, Sung H, Kim MN, Kim DY, Lee JH, Lee JH, Lee KH, Kim SH.
    J Antimicrob Chemother; 2012 Jun 15; 67(6):1486-92. PubMed ID: 22354954
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.